ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1704

Tofacitinib in Rheumatoid Arthritis: Is There a Correlation Between a Rapid Analgesic Effect and a Decrease in Activity After 3 and 6 Months?

Elena Pogozheva1, Andrey Karateev1, Evgeniy Nasonov1, Alexander Lila1, Vadim Mazurov2, Rusanna Samigullina3, Diana Chakieva4, Anna Dadalova4, Anna Dyo4, Andrey Baranov5, Natalia Lapkina5, Ekaterina Kol’tsova6, Ivan Shchendrigin7, Tatyana Rasevich8, Antonina Davydova9, Irina Shafieva10, Inna Bashkova11, Daria Bobrikova12, Irina Kushnir13, Elena Kalinina14, Tatiana Sal’nikova15, Valentina Sorotskaya16, Irina Marusenko17, Olga Semagina18, Irina Vinogradova19, Diana Krechikova20, Natalia Kiryukhina21, Irina Semizarova22, Dzhamilya Murtazalieva23 and Marina Semchenkova24, 1V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia, 2Mechnikov North-Western State Medical University, Saint Petersburg, Russia, 3Mechnikov North-Western State Medical University, St.Petersburg, Russia, 4Mechnikov North-Western State Medical University, St. Petersburg, Russia, 5Yaroslavl State Medical University, Yaroslavl, Russia, 6Scientific and Research Institute of Health Care Organization, Moscow, Russia, 7Stavropol Regional Clinical Hospital, Stavropol, Russia, 8Astrakhan Region Alexandro-Mariinsky Regional Clinical Hospital, Astrakhan, Russia, 9Regional Clinical Hospital №1 named. prof. S. V. Ochapovskogo, Krasnodar, Russia, 10Samara State Medical University of the Ministry of Health of the Russian Federation, Samara, Russia, 11Advisory Polyclinic Chuvash State University named after I. N. Ulyanov, Cheboksary, Russia, 12Regional Clinical Hospital No. 1, Tyumen', Russia, 13Kemerovo regional clinical hospital, Kemerovo, Russia, 14Volgograd State Medical University, Volgograd, Russia, 15Regional Clinical Hospital, Tula, Russia, 16Tula State Medical University, Tula, Russia, 17Petrozavodsk State University, Petrozavodsk, Russia, 18Regional Clinical Hospital, Samara, Russia, 19Regional Clinical Hospital, Ulyanovsk, Russia, 20Smolensk State Medical University, Smolensk, Russia, 21National Medical and Surgical Center named after N.I. Pirogov” of the Ministry of Healthcare of the Russian Federation, Moscow, Russia, 22Regional Clinical Hospital, Krasnodar, Russia, 23Moscow Clinical Scientific and Practical Centre named after Loginov A.S., Moscow, Russia, 24Medical Clinical Centre, Smolensk, Russia

Meeting: ACR Convergence 2021

Keywords: central sensitization, Disease Activity, pain, rheumatoid arthritis, Tofacitinib

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Session Title: RA – Treatments Poster III: RA Treatments & Their Safety (1674–1710)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: to investigate the correlation between the rapid analgesic effect of tofacitinib and a decrease in RA activity after 3 and 6 months.

Methods: The study group consisted of 88 RA patients, age 53±11.5, 79.3% women, 89.8% RF “+”, DAS28 5.2±1.2, who received DMARDs (59.5% methotrexate and 19.8% leflunomide), who had ineffectiveness or intolerance to biological therapy. All patients were prescribed tofacitinib 10 mg / day. The severity of pain was assessed using the Brief pain inventory (BPI) questionnaire, the presence of a neuropathic pain component (NPC) using the painDETECT questionnaire, and signs of central sensitization (CS) using the Central Sensitivity Inventory (CSI) questionnaire in the early stages after tofacitinib administration, and RA activity by DAS28 at 3 and 6 months.

Results: Pain intensity at baseline was 5.3±2.0 on the visual analog scale (VAS 0-10), 51.1% of patients had signs of central sensitization (CSI ≥ 40), 15.9% had NPC (painDETECT ≥18). 7 days after starting tofacitinib, there was a statistically significant decrease in pain intensity – to 4.1±1.8 (p< 0.05) and CS-CSI from 40.4±13.5 to 36.5±12.5 (p=0.01). After 28 days, the pain intensity (VAS) was 2.8±1.6 (p=0.000), painDETECT decreased from 11.8±5.6 to 6.8± 3.1 (p=0.000), CSI to 31.6±13.9 (p=0.000). DAS28 after 3 and 6 months was 3.7±1.3 and 3.6±1.2. The number of patients with pain reduction ≥ 50% after 28 days of therapy was 59.9%. Low RA activity after 3 months (DAS28 ≤3.2) was achieved in 64.4% of patients. This was a clear correlation between the number of patients with significant pain reduction after 28 days and the number of patients who achieved low RA activity after 3 and 6 months (rS=0.548, p=0.000; rS=0.790, p=0.000). 6 patients dropped out of the study due to inefficiency or social reasons. No serious adverse reactions were observed.

Conclusion: Tofacitinib rapidly reduces the intensity of pain and signs of CS in RA. A quick response to this drug (pain reduction) makes it possible to predict a decrease in RA activity after 3 and 6 months of therapy.


Disclosures: E. Pogozheva, None; A. Karateev, None; E. Nasonov, Eli Lilly, 2, Abbvie, 2, Pfizer, 2, Hoffmann-La Roche, 2, Biocad, 2, R-Pharm, 2; A. Lila, None; V. Mazurov, None; R. Samigullina, None; D. Chakieva, None; A. Dadalova, None; A. Dyo, None; A. Baranov, None; N. Lapkina, None; E. Kol’tsova, None; I. Shchendrigin, None; T. Rasevich, None; A. Davydova, None; I. Shafieva, None; I. Bashkova, None; D. Bobrikova, None; I. Kushnir, None; E. Kalinina, None; T. Sal’nikova, None; V. Sorotskaya, None; I. Marusenko, None; O. Semagina, None; I. Vinogradova, None; D. Krechikova, None; N. Kiryukhina, None; I. Semizarova, None; D. Murtazalieva, None; M. Semchenkova, None.

To cite this abstract in AMA style:

Pogozheva E, Karateev A, Nasonov E, Lila A, Mazurov V, Samigullina R, Chakieva D, Dadalova A, Dyo A, Baranov A, Lapkina N, Kol’tsova E, Shchendrigin I, Rasevich T, Davydova A, Shafieva I, Bashkova I, Bobrikova D, Kushnir I, Kalinina E, Sal’nikova T, Sorotskaya V, Marusenko I, Semagina O, Vinogradova I, Krechikova D, Kiryukhina N, Semizarova I, Murtazalieva D, Semchenkova M. Tofacitinib in Rheumatoid Arthritis: Is There a Correlation Between a Rapid Analgesic Effect and a Decrease in Activity After 3 and 6 Months? [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/tofacitinib-in-rheumatoid-arthritis-is-there-a-correlation-between-a-rapid-analgesic-effect-and-a-decrease-in-activity-after-3-and-6-months/. Accessed January 30, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tofacitinib-in-rheumatoid-arthritis-is-there-a-correlation-between-a-rapid-analgesic-effect-and-a-decrease-in-activity-after-3-and-6-months/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences